Scandinavian ChemoTech AB Series B Cash Flow Conversion Efficiency

Latest as of June 2026: -1.171x

Scandinavian ChemoTech AB Series B cash flow conversion efficiency. Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has a cash flow conversion efficiency ratio of -1.171x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.78 Million ≈ $-191.56K USD) by net assets (Skr1.52 Million ≈ $163.58K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Scandinavian ChemoTech AB Series B (2014–2025)

Cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2025. This chart illustrates how Scandinavian ChemoTech AB Series B's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Scandinavian ChemoTech AB Series B share price for real-time trading data and today's change.

Scandinavian ChemoTech AB Series B Cash Flow Conversion Ratio Explained

Scandinavian ChemoTech AB Series B cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Scandinavian ChemoTech AB Series B Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their cash flow conversion efficiency. Also see market cap of Scandinavian ChemoTech AB Series B for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ASKOLL EVA S.P.A. F:736	N/A
Swift Networks Group Ltd AU:SW1	-0.012x
Omineca Mining and Metals Ltd V:OMM	-0.046x
Metal Hawk Ltd AU:MHK	-0.079x
Palash Securities Limited NSE:PALASHSECU	-0.045x
Holand og Setskog Sparebank OL:HSPG	0.251x
Akkhie Prakarn Public Company Limited BK:AKP	0.036x
Fourth-Link Inc. KQ:056730	0.045x

Annual Cash Flow Conversion Efficiency for Scandinavian ChemoTech AB Series B (2014–2025)

The table below shows the annual cash flow conversion efficiency of Scandinavian ChemoTech AB Series B from 2014 to 2025. Review Scandinavian ChemoTech AB Series B (CMOTEC-B) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr3.19 Million ≈ $342.86K	Skr-3.75 Million ≈ $-403.02K	-1.175x	+46.53%
2024-12-31	Skr5.98 Million ≈ $643.54K	Skr-13.14 Million ≈ $-1.41 Million	-2.198x	-33.04%
2023-12-31	Skr11.03 Million ≈ $1.19 Million	Skr-18.23 Million ≈ $-1.96 Million	-1.652x	-17.77%
2022-12-31	Skr13.99 Million ≈ $1.51 Million	Skr-19.63 Million ≈ $-2.11 Million	-1.403x	-74.92%
2021-12-31	Skr23.92 Million ≈ $2.57 Million	Skr-19.18 Million ≈ $-2.06 Million	-0.802x	+12.79%
2020-12-31	Skr9.24 Million ≈ $993.94K	Skr-8.49 Million ≈ $-914.09K	-0.920x	+20.30%
2019-12-31	Skr9.73 Million ≈ $1.05 Million	Skr-11.23 Million ≈ $-1.21 Million	-1.154x	-416.46%
2018-12-31	Skr20.50 Million ≈ $2.21 Million	Skr-4.58 Million ≈ $-492.77K	-0.223x	+84.65%
2017-12-31	Skr10.29 Million ≈ $1.11 Million	Skr-14.97 Million ≈ $-1.61 Million	-1.456x	-182.40%
2016-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-7.52 Million ≈ $-808.93K	-0.515x	+5.74%
2015-12-31	Skr868.64K ≈ $93.48K	Skr-474.99K ≈ $-51.12K	-0.547x	+38.15%
2014-12-31	Skr46.27K ≈ $4.98K	Skr-40.91K ≈ $-4.40K	-0.884x	--

About Scandinavian ChemoTech AB Series B

ST:CMOTEC-B Sweden Biotechnology

Market Cap

$8.71 Million

Skr80.93 Million SEK

Market Cap Rank

#27273 Global

#589 in Sweden

Share Price

Skr3.40

Change (1 day)

+5.92%

52-Week Range

Skr3.04 - Skr5.26

All Time High

Skr51358.02